The American Association for Cancer Research (AACR)-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology will be presented to Kenneth M. Murphy, MD, PhD, during the AACR Annual Meeting 2026, to be held April 17-22 at the San Diego Convention Center in San Diego, California.

A three-dimensional experimental system has been developed to study the response to drugs in low-grade glioma, a tumor of the central nervous system that often occurs in children. The project, developed by the University of Trento, Bambino Gesù Children's Hospital and Sapienza University of Rome, is a breakthrough in the study, understanding and treatment of the disease. 

The organoids make it possible to observe the disease in a slightly more realistic environment, compared to single-layer cell cultures, and to improve drug screening before carrying out clinical trials with patients. The group of researchers has therefore developed organoids from pluripotent stem cells and used them to develop the tumor.

Novel blood-based biomarker predicts cancer risk in patients with Lynch Syndrome

New epigenetic target sensitizes pancreatic tumors to immunotherapy

Promising strategy may help to overcome radiotherapy resistance in lung cancer

High dose radiation therapy improves outcomes for patients with bile duct tumors

About The Study: In this cross-sectional study, unmet health-related social needs were associated with lower colorectal cancer screening uptake, particularly among adults ages 50 to 64. Addressing health-related social needs may support age-specific strategies to improve colorectal cancer screening.

About The Study: Adults 75 years of age or older with adenoma at prior colonoscopy were more likely to experience subsequent colorectal cancer (CRC) and CRC death compared with those without adenoma, but cumulative risks were low and were far exceeded by competing risks for non-CRC death. Older adults may consider deprioritizing surveillance colonoscopy relative to other health concerns.

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will present new research at the American Association for Cancer Research (AACR) Annual Meeting, highlighting advances in targeted therapies, cancer immunology, early detection and treatment strategies across a range of tumor types. 

Better cancer care depends on better treatment options. That’s why the Ontario Institute for Cancer Research (OICR) is supporting four Ontario-based research teams working to develop the next generation of cancer therapies that are designed to be more effective at destroying tumours, have reduced side effects, and make cancer less likely to return. These projects take aim at breast and ovarian cancers, a hard-to-treat form of leukemia, the most aggressive form of the most common childhood brain cancer and a ‘master regulator’ protein that plays a role in many different cancers.